The US Supreme Court’s unanimous decision to dismiss a challenge to the US Food and Drug Administration’s regulation of the abortion pill mifepristone on the grounds the plaintiff lacked standing sets a high bar for future legal challenges of the agency's decisions.
Key Takeaways
-
The unanimous Supreme Court ruling in the mifepristone case will limit the types of challenges that can be brought against FDA approval decisions and create some stability and predictability for industry.
-
But the court’s decision not to opine on the case's merits still leaves some health care and legal experts worried about future blows to the agency’s regulatory authority
But the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?